<DOC>
	<DOCNO>NCT01721109</DOCNO>
	<brief_summary>This study evaluate steady-state pharmacokinetics ( PK ) confirm dose elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate ( EVG/COBI/FTC/TDF ) single tablet regimen ( STR ) HIV-1 infect , antiretroviral ( ARV ) treatment-naive adolescent . Safety , tolerability , efficacy also evaluate Week 48 . A total 50 adolescent participant ( 12 &lt; 18 year age ) enrol receive EVG/COBI/FTC/TDF follow : - Part A : Twelve 16 eligible participant enrol evaluate steady-state PK , confirm dose , intent enroll least 4 participant 12 &lt; 15 least 4 participant 15 &lt; 18 year age . - Part B : Following confirmation EVG exposure least 12 participant Part A , 34 38 participant addition enrol Part A enrolled evaluate safety , tolerability antiviral activity EVG/COBI/FTC/TDF STR .</brief_summary>
	<brief_title>Pharmacokinetics , Safety , Efficacy Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen ( STR ) Adolescents</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Key 12 year &lt; 18 year age baseline Able give write assent prior screen evaluation Parent guardian able give write informed consent prior screen evaluation willing comply study requirement Plasma HIV1 RNA level ≥ 1,000 copies/mL CD4+ cell count &gt; 100 cells/µL Weight ≥ 35 kg ( 77 lb ) Screening genotype report must show sensitivity FTC TDF Able swallow oral tablet Adequate renal function Clinically normal ECG Documented screen active pulmonary tuberculosis per local standard care within 6 month screen visit Hepatic transaminases ≤ 5 x upper limit normal Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Individuals positive Hepatitis B surface antigen screen test participate study , provide alternate therapy ( TDF ) chronic Hepatitis B infection available part local standard care Adequate hematologic function Negative serum pregnancy test female Males female childbearing potential must agree utilize highly effective contraception method study treatment agree abstain heterosexual intercourse throughout study period 30 day follow last dose study drug Males must agree utilize highly effective method contraception heterosexual intercourse throughout study period 30 day follow discontinuation investigational medicinal product Must willing able comply study requirement Life expectancy ≥ 1 year Key A new AIDSdefining condition diagnose within 30 day prior screen Prior treatment approve investigational experimental anti HIV1 drug length time ( give prevention mothertochild transmission ) Evidence active pulmonary extrapulmonary tuberculosis disease within 3 month screen visit Anticipated require rifamycin treatment mycobacterial infection participate study . Note : prophylactic Isoniazid ( INH ) therapy latent tuberculosis ( TB ) treatment allow . Individuals experience decompensated cirrhosis Pregnant lactating female Have serious active medical psychiatric illness would interfere treatment , assessment , compliance protocol . This would include uncontrolled renal , cardiac , hematological , hepatic , pulmonary , endocrine , central nervous , gastrointestinal , vascular , metabolic , immunodeficiency disorder , active infection , malignancy clinically significant require treatment within 30 day prior study dose . Current alcohol substance abuse potentially interfere compliance Have history significant drug sensitivity drug allergy Known hypersensitivity study drug , metabolite formulation excipients Have treat immunosuppressant therapy chemotherapeutic agent within 3 month study screen expect receive agent study A history malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Have previously participate investigational trial involve administration investigational agent within 30 day prior study dose Participation clinical trial without prior approval sponsor prohibit participate trial Receiving ongoing therapy disallow medication , include drug use EVG , COBI , FTC , TDF individual know allergy excipients EVG/COBI/FTC/TDF STR tablet Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adolescents</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>